Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
26
HLNCF Quote, Financials, Valuation and Earnings
Last price:
$5.2200
Seasonality move
:
8.93%
Day range:
$5.1500 - $5.4500
52-week range:
$4.2500 - $5.8000
Dividend yield:
1.77%
P/E ratio:
21.11x
P/S ratio:
3.23x
P/B ratio:
2.03x
Volume:
1K
Avg. volume:
97.6K
1-year change:
1.98%
Market cap:
$45.9B
Revenue:
$14.5B
EPS (TTM):
$0.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HLNCF
Haleon Plc
|
$3.7B | -- | 1.58% | -- | -- |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
OXBDF
Oxford Biomedica Plc
|
-- | -- | -- | -- | -- |
|
SLNCF
Silence Therapeutics Plc
|
$1.6M | -$0.15 | 700.8% | -12.5% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HLNCF
Haleon Plc
|
$5.1500 | -- | $45.9B | 21.11x | $0.03 | 1.77% | 3.23x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$1.13 | $17.94 | $947.8K | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$2.19 | $104.00 | $9.1M | -- | $0.00 | 0% | -- |
|
OXBDF
Oxford Biomedica Plc
|
$8.40 | -- | $1B | -- | $0.00 | 0% | 4.55x |
|
SLNCF
Silence Therapeutics Plc
|
$1.60 | -- | $226.7M | -- | $0.00 | 0% | 112.71x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HLNCF
Haleon Plc
|
38.17% | -0.480 | -- | 0.75x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.310 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.482 | 0.95% | 4.03x |
|
OXBDF
Oxford Biomedica Plc
|
37.49% | 2.408 | -- | 1.99x |
|
SLNCF
Silence Therapeutics Plc
|
0.25% | 4.622 | 0.09% | 5.88x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HLNCF
Haleon Plc
|
$2B | $448.1M | 5.64% | 8.91% | 14.46% | $921M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
OXBDF
Oxford Biomedica Plc
|
-- | -- | -90.47% | -120.93% | -- | -- |
|
SLNCF
Silence Therapeutics Plc
|
-$20.5K | -$23.7M | -101.67% | -101.79% | -14881.13% | -$11M |
Haleon Plc vs. Competitors
-
Which has Higher Returns HLNCF or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of 8.37% compared to Haleon Plc's net margin of --. Haleon Plc's return on equity of 8.91% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital HLNCFHaleon Plc55.38% $0.03 $32.9B BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About HLNCF or BDRX?
Haleon Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 15639.05%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Haleon Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Haleon Plc.
Company Buy Ratings Hold Ratings Sell Ratings HLNCFHaleon Plc0 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is HLNCF or BDRX More Risky?
Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.469%.
-
Which is a Better Dividend Stock HLNCF or BDRX?
Haleon Plc has a quarterly dividend of $0.03 per share corresponding to a yield of 1.77%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 38.18% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLNCF or BDRX?
Haleon Plc quarterly revenues are $3.5B, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Haleon Plc's net income of $295.8M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Haleon Plc's price-to-earnings ratio is 21.11x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.23x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNCFHaleon Plc3.23x 21.11x $3.5B $295.8M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns HLNCF or NCNA?
NuCana Plc has a net margin of 8.37% compared to Haleon Plc's net margin of --. Haleon Plc's return on equity of 8.91% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital HLNCFHaleon Plc55.38% $0.03 $32.9B NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About HLNCF or NCNA?
Haleon Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 949671.69%. Given that NuCana Plc has higher upside potential than Haleon Plc, analysts believe NuCana Plc is more attractive than Haleon Plc.
Company Buy Ratings Hold Ratings Sell Ratings HLNCFHaleon Plc0 0 0 NCNANuCana Plc0 1 0 -
Is HLNCF or NCNA More Risky?
Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.677, suggesting its more volatile than the S&P 500 by 67.66%.
-
Which is a Better Dividend Stock HLNCF or NCNA?
Haleon Plc has a quarterly dividend of $0.03 per share corresponding to a yield of 1.77%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 38.18% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLNCF or NCNA?
Haleon Plc quarterly revenues are $3.5B, which are larger than NuCana Plc quarterly revenues of --. Haleon Plc's net income of $295.8M is higher than NuCana Plc's net income of -$378.9K. Notably, Haleon Plc's price-to-earnings ratio is 21.11x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.23x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNCFHaleon Plc3.23x 21.11x $3.5B $295.8M NCNANuCana Plc-- -- -- -$378.9K
-
Which has Higher Returns HLNCF or OXBDF?
Oxford Biomedica Plc has a net margin of 8.37% compared to Haleon Plc's net margin of --. Haleon Plc's return on equity of 8.91% beat Oxford Biomedica Plc's return on equity of -120.93%.
Company Gross Margin Earnings Per Share Invested Capital HLNCFHaleon Plc55.38% $0.03 $32.9B OXBDFOxford Biomedica Plc-- -- $140.3M -
What do Analysts Say About HLNCF or OXBDF?
Haleon Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Oxford Biomedica Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Haleon Plc has higher upside potential than Oxford Biomedica Plc, analysts believe Haleon Plc is more attractive than Oxford Biomedica Plc.
Company Buy Ratings Hold Ratings Sell Ratings HLNCFHaleon Plc0 0 0 OXBDFOxford Biomedica Plc0 0 0 -
Is HLNCF or OXBDF More Risky?
Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oxford Biomedica Plc has a beta of 1.082, suggesting its more volatile than the S&P 500 by 8.226%.
-
Which is a Better Dividend Stock HLNCF or OXBDF?
Haleon Plc has a quarterly dividend of $0.03 per share corresponding to a yield of 1.77%. Oxford Biomedica Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 38.18% of its earnings as a dividend. Oxford Biomedica Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLNCF or OXBDF?
Haleon Plc quarterly revenues are $3.5B, which are larger than Oxford Biomedica Plc quarterly revenues of --. Haleon Plc's net income of $295.8M is higher than Oxford Biomedica Plc's net income of --. Notably, Haleon Plc's price-to-earnings ratio is 21.11x while Oxford Biomedica Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.23x versus 4.55x for Oxford Biomedica Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNCFHaleon Plc3.23x 21.11x $3.5B $295.8M OXBDFOxford Biomedica Plc4.55x -- -- --
-
Which has Higher Returns HLNCF or SLNCF?
Silence Therapeutics Plc has a net margin of 8.37% compared to Haleon Plc's net margin of -13181.13%. Haleon Plc's return on equity of 8.91% beat Silence Therapeutics Plc's return on equity of -101.79%.
Company Gross Margin Earnings Per Share Invested Capital HLNCFHaleon Plc55.38% $0.03 $32.9B SLNCFSilence Therapeutics Plc-12.89% -$0.15 $74.2M -
What do Analysts Say About HLNCF or SLNCF?
Haleon Plc has a consensus price target of --, signalling downside risk potential of --. On the other hand Silence Therapeutics Plc has an analysts' consensus of -- which suggests that it could fall by --. Given that Haleon Plc has higher upside potential than Silence Therapeutics Plc, analysts believe Haleon Plc is more attractive than Silence Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings HLNCFHaleon Plc0 0 0 SLNCFSilence Therapeutics Plc1 0 0 -
Is HLNCF or SLNCF More Risky?
Haleon Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Silence Therapeutics Plc has a beta of 0.776, suggesting its less volatile than the S&P 500 by 22.438%.
-
Which is a Better Dividend Stock HLNCF or SLNCF?
Haleon Plc has a quarterly dividend of $0.03 per share corresponding to a yield of 1.77%. Silence Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Haleon Plc pays 38.18% of its earnings as a dividend. Silence Therapeutics Plc pays out -- of its earnings as a dividend. Haleon Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HLNCF or SLNCF?
Haleon Plc quarterly revenues are $3.5B, which are larger than Silence Therapeutics Plc quarterly revenues of $159K. Haleon Plc's net income of $295.8M is higher than Silence Therapeutics Plc's net income of -$21M. Notably, Haleon Plc's price-to-earnings ratio is 21.11x while Silence Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Haleon Plc is 3.23x versus 112.71x for Silence Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HLNCFHaleon Plc3.23x 21.11x $3.5B $295.8M SLNCFSilence Therapeutics Plc112.71x -- $159K -$21M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 14.29% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 7.51% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 5.73% over the past day.
